undamentalytics Newsletter
Sign in

Atara Biotherapeutics, Inc. (ATRA) stock

Add to watchlist

Add holding +

NASDAQ: ATRA Nasdaq Biotechnology Next results ~November 12, 2026

Atara Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Atara Biotherapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Atara Biotherapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 4 selling2 purchases and 18 sales by directors and officers, last 12 monthsInsider trades
  • Funds16 adding, 9 cuttingOf 7 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Atara Biotherapeutics files

Where Atara Biotherapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $6m, down 96.7% on a year earlier, a steeper fall than the 88.4% decline a quarter earlier. Free-cash-flow margin fell to -353.5% from -33.9% a year earlier. Operating margin narrowed to -229.7% from 4.3%. It passes 1 of our 3 financial-health checks.

Our model value for Atara Biotherapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Atara Biotherapeutics, Inc.'s trailing-twelve-month revenue fell 96.7% year on year, with a free-cash-flow margin of -353.5%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -96.7% (-8.3pp vs the prior quarter), the 7th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 96.7% over the last 12 months.
  • Growth slowing. The growth rate is 8.3 points lower than a quarter earlier.
  • Loss-making. Operating margin is -229.7%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 233.9 points on a year ago.
  • Burning cash. Free cash flow was -353.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 62.7% of revenue: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
-$0.32 against an average estimate of -$0.25: missed by 28.0%
Revenue
$1m, down 96.4% on a year earlier
Share reaction
-4.8% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.22

Atara Biotherapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.9%
  • 1 week+1.6%
  • 1 month-10.5%
  • This year-53.1%
  • 1 year-42.9%
  • 5 years-98.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.2M
Operating margin
-229.7%
Net margin
-269.4%
EPS (TTM, diluted)
$-1.17

Growth

Revenue growth
−96.7%
Change in growth rate
−8.3 pts

Cash

Free cash flow (TTM)
-$21.9M
FCF margin
-353.5%
Stock pay % of revenue
62.7%

Earnings

Last results
August 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Atara Biotherapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Atara Biotherapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.06 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.8 ~$1.8–$6.1 Left out: out of range vs price (0.09x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Atara Biotherapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$82.00$12.82$13.31$18.09$8.48
Market value$335m$54m$100m$230m$120m
+ Net debt (− = net cash)−$93m−$26m−$25m−$8m−$3m
Enterprise value$242m$28m$75m$222m$117m
Multiples
Price / sales 5.3x6.3x0.8x1.9x19.4x
Price / earnings ———7.0x—
Price / free cash flow —————
EV / EBITDA ———5.8x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $533330 and EPS of −$0.22 (range −$0.33 to −$0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.95 −137% $3m −98%
Next $1.54 +263% $41m +1335%

Next year's EPS estimate has moved −5.6% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −22.8% on 90 days ago. In the last 30 days, 0 analysts raised Atara Biotherapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Atara Biotherapeutics, Inc., last 90 days
−$2.00 −$1.00 $0.00 $1.00 $2.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.23 Current fiscal year, 60 days ago: −$0.88 Current fiscal year, 30 days ago: −$0.88 Current fiscal year, 7 days ago: −$1.27 Current fiscal year, Now: −$0.95 −$0.95 Next fiscal year, 90 days ago: $1.64 Next fiscal year, 60 days ago: $1.27 Next fiscal year, 30 days ago: $1.27 Next fiscal year, 7 days ago: $1.56 Next fiscal year, Now: $1.54 $1.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.23$1.64
60 days ago −$0.88$1.27
30 days ago −$0.88$1.27
7 days ago −$1.27$1.56
Now −$0.95$1.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.25 −$0.32 −28.0%
Dec 2025 −$0.10 −$0.35 −238.7%
Sept 2025 −$0.67 −$0.32 +51.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 12, 2026

No numeric guidance in Atara Biotherapeutics, Inc.'s latest earnings release (filed August 12, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

3 analysts, Oct 2026
Buy267%
Hold133%
Sell00%

Monthly trend

  1. Oct 2026213
  2. Sep 2026314

Counts of recommendations published by analysts covering Atara Biotherapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.8%
of tradable shares
Days to cover
8.52
at average volume
Short interest, 1 month
−13%
to October 15, 2026
Held by institutions
58%
of shares
Held by insiders
16.8%
of shares
Employees
10
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ATRA−20%−79%−84%+4%+36%−53%
Industry peers (median)−36%−56%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ATRA33%25%33%58%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ATRA−42%−83%−96%−78%−71%−77%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from May 21, 2018 to February 20, 2026. Getting back needed a 30672% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.18 – $18.09
From 52-week high
−53.1%
vs 50-day average
−7.5%
vs 200-day average
+10.2%
Volatility (1 year)
143%
Beta vs S&P 500
1.10

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±16.8%
After a week
7 up, 5 down
typical move ±17.5%
After a month
6 up, 6 down
typical move ±22.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −4.8% +0.9% +7.4% +4.9%
March 16, 2026 −19.5% +1.3% −25.5% −19.4%
January 12, 2026 −68.0% 0.0% −68.4% −66.4%
November 12, 2025 +6.6% −1.6% +9.4% +43.3%
August 11, 2025 +5.3% +0.9% +4.8% +7.5%
July 14, 2025 +0.4% −0.2% +24.6% +25.0%
May 15, 2025 +3.5% +1.1% +7.6% +29.8%
March 7, 2025 −9.4% −2.1% +6.6% −15.7%
January 16, 2025 −50.1% +0.8% −37.5% −38.6%
November 12, 2024 +21.2% −0.3% −6.6% −7.0%
August 12, 2024 +5.8% +1.7% −5.1% +9.6%
May 9, 2024 −6.4% +0.7% +6.7% −7.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Atara Biotherapeutics, Inc.
$0 $50M $100M $150M $200M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $4.5M Revenue (TTM), FY23 Q4: $8.6M Revenue (TTM), FY24 Q1: $34.7M Revenue (TTM), FY24 Q2: $62.4M Revenue (TTM), FY24 Q3: $100.4M Revenue (TTM), FY24 Q4: $128.9M Revenue (TTM), FY25 Q1: $199.7M Revenue (TTM), FY25 Q2: $188.7M Revenue (TTM), FY25 Q3: $151.9M Revenue (TTM), FY25 Q4: $120.8M Revenue (TTM), FY26 Q1: $23.1M Revenue (TTM), FY26 Q2: $6.2M $6.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $4.5M
FY23 Q4 $8.6M
FY24 Q1 $34.7M
FY24 Q2 $62.4M
FY24 Q3 $100.4M
FY24 Q4 $128.9M
FY25 Q1 $199.7M
FY25 Q2 $188.7M
FY25 Q3 $151.9M
FY25 Q4 $120.8M
FY26 Q1 $23.1M
FY26 Q2 $6.2M
Revenue growth, TTM YoY Atara Biotherapeutics, Inc.
-1000% 0% 1000% 2000% 3000% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY23 Q4: -86.5% Revenue growth, TTM YoY, FY24 Q1: -39.6% Revenue growth, TTM YoY, FY24 Q2: 809.0% Revenue growth, TTM YoY, FY24 Q3: 2111.3% Revenue growth, TTM YoY, FY24 Q4: 1404.0% Revenue growth, TTM YoY, FY25 Q1: 475.5% Revenue growth, TTM YoY, FY25 Q2: 202.4% Revenue growth, TTM YoY, FY25 Q3: 51.3% Revenue growth, TTM YoY, FY25 Q4: -6.3% Revenue growth, TTM YoY, FY26 Q1: -88.4% Revenue growth, TTM YoY, FY26 Q2: -96.7% -96.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -86.5%
FY24 Q1 -39.6%
FY24 Q2 809.0%
FY24 Q3 2111.3%
FY24 Q4 1404.0%
FY25 Q1 475.5%
FY25 Q2 202.4%
FY25 Q3 51.3%
FY25 Q4 -6.3%
FY26 Q1 -88.4%
FY26 Q2 -96.7%
Operating margin (TTM) Atara Biotherapeutics, Inc.
-8000% -6000% -4000% -2000% 0% 2000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -6419.7% Operating margin (TTM), FY23 Q4: -3219.5% Operating margin (TTM), FY24 Q1: -669.2% Operating margin (TTM), FY24 Q2: -287.0% Operating margin (TTM), FY24 Q3: -130.6% Operating margin (TTM), FY24 Q4: -64.7% Operating margin (TTM), FY25 Q1: -6.7% Operating margin (TTM), FY25 Q2: 4.3% Operating margin (TTM), FY25 Q3: 17.3% Operating margin (TTM), FY25 Q4: 29.7% Operating margin (TTM), FY26 Q1: -27.3% Operating margin (TTM), FY26 Q2: -229.7% -229.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -6419.7%
FY23 Q4 -3219.5%
FY24 Q1 -669.2%
FY24 Q2 -287.0%
FY24 Q3 -130.6%
FY24 Q4 -64.7%
FY25 Q1 -6.7%
FY25 Q2 4.3%
FY25 Q3 17.3%
FY25 Q4 29.7%
FY26 Q1 -27.3%
FY26 Q2 -229.7%
FCF margin (TTM) Atara Biotherapeutics, Inc.
-6000% -4000% -2000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -4418.0% FCF margin (TTM), FY23 Q4: -2265.3% FCF margin (TTM), FY24 Q1: -533.4% FCF margin (TTM), FY24 Q2: -228.4% FCF margin (TTM), FY24 Q3: -94.4% FCF margin (TTM), FY24 Q4: -53.5% FCF margin (TTM), FY25 Q1: -33.7% FCF margin (TTM), FY25 Q2: -33.9% FCF margin (TTM), FY25 Q3: -45.9% FCF margin (TTM), FY25 Q4: -42.2% FCF margin (TTM), FY26 Q1: -111.8% FCF margin (TTM), FY26 Q2: -353.5% -353.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -4418.0%
FY23 Q4 -2265.3%
FY24 Q1 -533.4%
FY24 Q2 -228.4%
FY24 Q3 -94.4%
FY24 Q4 -53.5%
FY25 Q1 -33.7%
FY25 Q2 -33.9%
FY25 Q3 -45.9%
FY25 Q4 -42.2%
FY26 Q1 -111.8%
FY26 Q2 -353.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Atara Biotherapeutics took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $121M
  2. Research and development $37.4M · 31.0%
  3. Selling, general and admin $26.3M · 21.7%
  4. Other operating costs $21.2M · 17.6%
  5. Operating income $35.9M · 29.7%
  6. Interest and other $3.1M · 2.6%
  7. Net income $32.7M · 27.1%

Shares of revenue. Source: Atara Biotherapeutics's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 64 9 129 121 6
EBITDA −275 −271 −78 38 −14
Operating income −281 −276 −83 36 −14
Net income −228 −276 −85 33 −17
Diluted EPS −$2.24 −$65.19 −$11.41 $2.57 −$1.17
Growth (year on year)
Revenue — −86.5% +>999% −6.3% −96.7%
EBITDA — — — — −219.8%
Operating income — — — — −277.0%
Net income — — — — −388.0%
Margins
EBITDA margin −432.4% <−999% −60.8% 31.4% −227.6%
Operating margin −441.2% <−999% −64.7% 29.7% −229.7%
Net margin −359.1% <−999% −66.2% 27.1% −269.4%
Free-cash-flow margin −432.0% <−999% −53.5% −42.2% −353.5%
Cash flow
Cash from operations −270 −193 −69 −51 −22
Capital spending 4 1 0 0 0
Free cash flow −275 −194 −69 −51 −22
Stock-based pay 54 45 27 10 4
Free cash flow after stock pay −328 −240 −96 −61 −26
Balance sheet
Cash 93 26 25 8 3
Total debt 0 0 0 0 0
Net debt (negative = net cash) −93 −26 −25 −8 −3
Diluted shares 4m 4m 7m 13m 14m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $21m
Short-term assets $14mLonger-term assets $7m
What it owes, and who funded it · $58m
Short-term liabilities $7mLonger-term liabilities $51mShareholders' equity $-37m
  • Short-term assets cover short-term liabilities $14m of assets due within a year against $7m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $14m short-term assets against $51m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$14m against $3m of interest.

From Atara Biotherapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
68.0%
of revenue
Days sales outstanding
19 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ATRA CGON FATE HCWB TSHA TCRX Median
Revenue, last 12 months $6m $6m $6m $7m $5m $7m $55m
Revenue growth, last 12 months −96.7% >999% −23.4% 700.2% −32.3% 2.2% 12.2%
Revenue growth, 3-year average −3.4% — −62.1% 20.4% — −24.3% 13.1%
Revenue growth, latest quarter −96.4% >999% 9.2% >999% −100.0% −65.8% 10.2%
Operating margin −229.7% <−999% <−999% −115.3% <−999% <−999% −191.1%
Operating margin, 3-year average −170.8% <−999% <−999% −856.2% <−999% <−999% −361.6%
Net margin −269.4% <−999% <−999% −83.8% <−999% <−999% −172.8%
Cash from operations / revenue −353.5% <−999% <−999% −182.1% <−999% <−999% −168.8%
Free-cash-flow margin −353.5% <−999% <−999% −182.1% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average −205.3% — <−999% −759.7% <−999% <−999% −306.5%
Stock pay / revenue 62.7% 567.2% 274.8% 3.4% 331.3% 138.4% 20.7%
Change in share count 4.0% 14.1% 1.2% −47.7% 31.1% 4.1% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$51.3M
Institutions reporting
35
Shares held vs prior quarter
▲ 74.2%
Positions opened / closed
4 / 1

Top buyers and sellers, Q2 2026: 16 institutions bought and 9 sold ; the biggest buyer was Ecor1 Capital, LLC (+1.5M shares) and the biggest seller Acadian Asset Management LLC (−92K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Ecor1 Capital, LLC $17.8M 1.6M 34.7% ▲ 1458.3%
Adage Capital Partners Gp, L.L.C. $9.8M 850K 19.0% ▲ 21.4%
Point72 Asset Management, L.P. $7.9M 688K 15.4% ▲ 254.0%
Redmile Group, LLC $5.1M 442K 9.9% 0.0%
Vanguard Capital Management LLC $2.8M 247K 5.5% ▲ 13.4%
Mackenzie Financial Corp $2.7M 233K 5.2% ▼ 25.6%
Blackrock, Inc. $969,544 84K 1.9% ▲ 6.9%
Geode Capital Management, LLC $862,924 75K 1.7% ▲ 13.6%
Staley Capital Advisers Inc $574,000 50K 1.1% 0.0%
Vanguard Fiduciary Trust Co $494,053 43K 1.0% ▲ 28.0%
Acadian Asset Management LLC $444,000 39K 0.9% ▼ 70.3%
Jane Street Group, LLC $348,360 30K 0.7% ▼ 10.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Atara Biotherapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $5.7M 2 trades by 2 insiders, last 12 months Insider sales History → $3.9M 18 trades by 4 insiders · 0% under pre-set plans
Net ▲ $1.9M net buying
Insider Date Trade Shares Price Value
Cherry Brian N Director September 4, 2026 Buy 104,166 $9.60 $999,994
Nguyen Anhco President and CEO August 17, 2026 Sell 5,062 $8.08 $40,901
Grant-Huerta Yanina Chief Accounting Officer May 18, 2026 Sell 2,414 $9.13 $22,040
Nguyen Anhco President and CEO May 18, 2026 Sell 5,241 $9.13 $47,850
Ecor1 Capital, Llc 10% owner May 7, 2026 Buy 507,407 $9.35 $4.7M
Panacea Innovation Ltd 10% owner May 7, 2026 Sell 313,446 $10.10 $3.2M
Nguyen Anhco President and CEO March 2, 2026 Sell 1,442 $5.09 $7,340
Nguyen Anhco President and CEO March 2, 2026 Sell 198 $5.08 $1,006
Nguyen Anhco President and CEO March 2, 2026 Sell 1,298 $5.09 $6,607
Nguyen Anhco President and CEO March 2, 2026 Sell 58 $5.08 $295
Grant-Huerta Yanina Chief Accounting Officer March 2, 2026 Sell 100 $5.08 $508
Grant-Huerta Yanina Chief Accounting Officer March 2, 2026 Sell 24 $5.08 $122

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 12, 2026
  • March 16, 2026
  • January 12, 2026
  • November 12, 2025
  • August 11, 2025
  • July 14, 2025

Recent SEC filings

Data status

When each part of this page on Atara Biotherapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Atara Biotherapeutics, Inc. in brief

What does Atara Biotherapeutics, Inc. do?
Atara Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Atara Biotherapeutics, Inc.'s stock ticker?
Atara Biotherapeutics, Inc. trades under the ticker ATRA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Atara Biotherapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Atara Biotherapeutics, Inc. reported revenue of $6.2M, 96.7% lower than a year earlier, according to its SEC filings.
What is Atara Biotherapeutics, Inc.'s free cash flow?
Atara Biotherapeutics, Inc.'s free-cash-flow margin is -353.5% of revenue over the trailing twelve months.
Who are Atara Biotherapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Ecor1 Capital, LLC, Adage Capital Partners Gp, L.L.C. and Point72 Asset Management, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Atara Biotherapeutics, Inc.'s market cap?
On November 2, 2026, Atara Biotherapeutics, Inc.'s market capitalisation was about $120M and net debt of -$3.2M. Market figures come from third-party market data and may be delayed.
Who are Atara Biotherapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Atara Biotherapeutics, Inc. are CG Oncology, Inc., Fate Therapeutics Inc, HCW Biologics Inc., Taysha Gene Therapies, Inc. and Tscan Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Atara Biotherapeutics, Inc.'s.
Are insiders buying or selling Atara Biotherapeutics, Inc. stock?
Over the last 12 months, Atara Biotherapeutics, Inc.'s directors and officers reported 2 open-market purchases and 18 sales on Form 4. The insider trading page charts every trade.
When is Atara Biotherapeutics, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Atara Biotherapeutics, Inc. announces its own schedule.